This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, H.-S. Articles by Wang, Y.-C. Search for Related Content PubMed PubMed Citation Articles by Hsu, H.-S. Articles by Wang, Y.-C.

Promoter Hypermethylation Is the Predominant Mechanism in hMLH1 and hMSH2 Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer

Authors' Affiliations: Division of Thoracic Surgery, Departments of ¹ Surgery and ² Pathology, Taipei Veterans General Hospital; ³ National Yang-Ming University Institute of Clinical Medicine; and ⁴ Department of Life Sciences, National Taiwan Normal University, Taipei, Taiwan

Requests for reprints: Yi-Ching Wang, Department of Life Sciences, National Taiwan Normal University, No. 88, Section 4, Tingchou Road, Taipei 116, Taiwan, R.O.C. Phone: 886-2-29336876 ext. 373; Fax: 886-2-29312904; E-mail: t43017{at}cc.ntnu.edu.tw.

Purpose and Experimental Design: The etiologic association and prognostic significance of mismatch repair gene/protein alterations have never been examined in nonsmoking lung cancer. Therefore, we investigated protein expression and promoter hypermethylation of hMLH1 and hMSH2 genes in the tumor specimens from 105 nonsmoking female non–small cell lung cancer (NSCLC) patients. Immunohistochemistry and restriction enzyme–based multiplex PCR were used to examine the protein expression and promoter hypermethylation, respectively. The occurrence of gene/protein alteration for each gene was compared with the patients' clinicopathologic variables as well as the overall survival and cancer-specific survival rates.

Results: Protein expression alteration and promoter hypermethylation were observed in 66% to 67% and 30% to 34% of tumor specimens for hMLH1 and hMSH2 genes, respectively. Loss of hMLH1 and hMSH2 protein expression was significantly associated with their promoter hypermethylation (P < 0.0001 and P = 0.049). The overall survival and cancer-specific survival rates were significantly lower in patients with promoter hypermethylation of hMSH2 gene than in those without hypermethylation (P = 0.038 and P = 0.004). The poor prognosis was still especially significant in adenocarcinoma (P = 0.035 and P = 0.061) and early-stage NSCLC patients (P = 0.067 and P = 0.041).

Conclusion: Our data suggest that hMLH1 is the major altered mismatch repair gene involved in nonsmoking NSCLC tumorigenesis and that promoter methylation is the predominant mechanism in hMLH1 and hMSH2 deregulation. In addition, promoter methylation of the hMSH2 gene may be a potential prognostic factor in nonsmoking female lung cancer.

This article has been cited by other articles:

				J. Wang, A. J. Sasco, C. Fu, H. Xue, G. Guo, Z. Hua, Q. Zhou, Q. Jiang, and B. Xu Aberrant DNA Methylation of P16, MGMT, and hMLH1 Genes in Combination with MTHFR C677T Genetic Polymorphism in Esophageal Squamous Cell Carcinoma Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 118 - 125. [Abstract] [Full Text] [PDF]

				Y. Tada, R. M. Brena, B. Hackanson, C. Morrison, G. A. Otterson, and C. Plass Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst, March 15, 2006; 98(6): 396 - 406. [Abstract] [Full Text] [PDF]